Mustang Bio Common Stock Net 2016-2025 | MBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Mustang Bio common stock net from 2016 to 2025. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Mustang Bio common stock net from 2016 to 2025. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$228.5B
Amgen (AMGN)	$165.9B
Gilead Sciences (GILD)	$140.8B
Vertex Pharmaceuticals (VRTX)	$121.3B
Bristol Myers Squibb (BMY)	$99.6B
CSL (CSLLY)	$86.2B
GSK (GSK)	$78.3B
Regeneron Pharmaceuticals (REGN)	$61B
Alnylam Pharmaceuticals (ALNY)	$42.8B
Argenex SE (ARGX)	$36.2B
BioNTech SE (BNTX)	$27.5B
Royalty Pharma (RPRX)	$20.6B
Insmed (INSM)	$19.6B
Biogen (BIIB)	$19.4B
Illumina (ILMN)	$17B
Genmab (GMAB)	$15.2B
Genmab (GNMSF)	$14.9B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.2B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.5B
QIAGEN (QGEN)	$11.4B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.3B
Exact Sciences (EXAS)	$9.2B
Bio-Techne Corp (TECH)	$9.2B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Legend Biotech (LEGN)	$8.1B
Roivant Sciences (ROIV)	$7.7B